Telithromycin

References

• Carbon C, Moola S, Velancsics I, Leroy B, Rangaraju M, Decosta P Telithromycin 800 mg once-daily for 7 to 10 days is an effective and well-tolerated treatment for community acquired pneumonia. Clin. Microb. Infect. 9, 691–703 (2003).
   Google Scholar
• Barlett JG, Dowell SF, Mandell LA, File TM, Musher DM, Fine MJ. Practice guidelines for the management of community acquired pneumonia in adults. Clin. Infect. Dis. 31,347–382 (2000).
   PubMedGoogle Scholar
• Garau J. Changing patterns of etiology and resistance in community acquired respiratory tract infections. Infect. Dis. Clin. Pract. 7 (Suppl. 2), 92–95 (1998).
   Google Scholar
• Doem G, Brown S. Antimicrobial susceptibility among community acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-2001. J. Infect. 48,56–65 (2004).
   PubMedGoogle Scholar
• ••Worldwide study showing commonrespiratory pathogens.
   Google Scholar
• Barman Balfour J, Figgitt D. Telithromycin. Drugs 61, 815–829 (2001).
   Google Scholar
• •Excellent in vitro activity information.
   Google Scholar
• Hyde T, Gay K, Stephens D, Vugia D, Pass M, Johnson S. Macrolide resistance among invasive Streptococcus pneumoniae isolates. J. Am. Med. Assoc. 286,1857–1862 (2001).
   PubMed Web of Science ®Google Scholar
• Davidson R, Cavalcanti R, Brunton J, Bast D, De Azavedo J, Kibsey B Resistance to levofloxacin and failure to treatment of pneumococcal pneumonia. N EngL J Med 346,747–750 (2002).
   PubMed Web of Science ®Google Scholar
• Zervos M, Hershberger E, Nicolau D, Ritchie D, Blackner K, Coyle E. Relationship between fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000. Clin. Infict Dis. 37, 1643–1648 (2003).
   PubMed Web of Science ®Google Scholar
• Nieman R, Sharma K, Edelberg H, Caffe S. Aventis correspondence — telithromycin and myasthenia gravis. Clin. Infect. Dis. 37,1579 (2003).
   PubMedGoogle Scholar
• Berisio R, Harms J, Schluenzen F, Zarivach R, Hansen H, Fucini P. Structural insight into the antibiotic action of telithromycin against resistant mutants. J. BacterioL 185, 4276–4279 (2003).
   PubMed Web of Science ®Google Scholar
• Zhanel G, Walters M, Ayman N, Vercaigne L, Wierzbowski A, Embil J. The ketolides: a critical review. Drugs 62(12), 1771–1804 (2002).
   PubMed Web of Science ®Google Scholar
• ••Excellent review of the subject.
   Google Scholar
• Pankuch G, Visalli M, Jacobs M, et al Susceptibilities of penicillin-and erythromycin-susceptible and-resistant pneumococd to HMR 3647 (RU66647), a new ketolide, compared with susceptibilities to 17 other agents. Antimicrob. Agents Chemother. 42, 624–630 (1998).
   PubMed Web of Science ®Google Scholar
• Odenholt I, Lowdin E, Cars O. Pharmacodynamics of telithromycin in vitro against respiratory track pathogens. Antimicrob. Agents Chemother. 45(1), 23–29 (2001).
   PubMedGoogle Scholar
• Boswell F, Andrews J, Wise R. Pharmacodynamic properties of HMR 3647, a novel ketolide, on respiratory pathogens, enterococci and Bacteroides fiagilis demonstrated by studies of time-kill kinetics and postantibiotic effect. J. Antimicrob. Chemother. 41, 149–153 (1998).
   PubMed Web of Science ®Google Scholar
• Bebear C, Renaudin H, Bryskier A, et al. Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas. Antimicrob. Agents Chemother. 44, 1980–1982 (2000).
   PubMed Web of Science ®Google Scholar
• Roblin P, Hammerschlag M. In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae. Antimicrob. Agents Chemother. 42, 1515–1516 (1998).
   PubMed Web of Science ®Google Scholar
• Edelstein P, Edelstein M. In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea-pigs, and use of the drug to treat guinea-pigs with Legionella pneumophila pneumonia. Antimicrob. Agents Chemother. 43, 90–95 (1999).
   PubMed Web of Science ®Google Scholar
• Rastogi N, Goh K, Berchel M, et al. In vitro activities of the ketolides telithromycin (HMR 3647) and HMR 3004 compared with those of darithromycin against slowly growing mycobacteria at pHs 6.8 and 7.4. Antimicrob. Agents Chemother. 44, 2848–2852 (2000).
   PubMed Web of Science ®Google Scholar
• Namour F, Wessels DH, Pascual MH, et al Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses. Antimicrob. Agents Chemother. 45(1), 170–175 (2001).
   PubMedGoogle Scholar
• •Excellent phannokinetic review.
   Google Scholar
• Gehanno P, Passot V, Nabet P, et al. Telithromycin (HMR 3647) penetrates rapidly into tonsillar tissue achieving high and prolonged tonsillar concentrations. Clin. Microbial Infect. 6\(Suppl. 1), 204 (2000).
   Google Scholar
• Muller-Serieys C, Cantalloube C, Soler P, et al. HMR 3647 achieves high and sustained concentrations in broncho-pulmonary tissues. J. Antimicrob. Chemother. 44(Suppl. A), 57 (1999) (Abstract P78).
   Google Scholar
• Miossec-Bartoli C, Pilatre L, Peyron P, et al. The new ketolide HMR 3647 accumulates in the azurophil granules of human polymorphonudear cells. Antimicrob. Agents Chemother. 43, 2457–2462 (1999).
   PubMed Web of Science ®Google Scholar
• Miyamoto N, Murakami S, Yajin K, et al. Pharmacokinetic study of a new ketolide antimicrobial telithromycin (HMR 3647) in otorhinolaryngology. Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada, 17–20 September 2000 (Abstract 2144).
   Google Scholar
• Sultan E, Namour F, Pascual MH, et al Penetration of the ketolide, HMR 3647, in cantharidin-induced blister fluid. Program and Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA, 24–27 September 1998 (Abstract A47).
   Google Scholar
• Edlund C, Alvan G, Barkholt L, et al. Pharmacokinetics and comparative effects of telithromycin (HMR 3647) and darithromycin on the oropharyngeal and intestinal microflora. J. Antimicrob. Chemother. 46, 741–749 (2000).
   PubMed Web of Science ®Google Scholar
• Clark J, Langston E. Ketolides: a new class of antibacterial agents for treatment of community acquired respiratory tract infections in a primary care setting. Mayo Clin. Proc. 78, 1113–1124 (2003).
   PubMedGoogle Scholar
• •Excellent efficacy information.
   Google Scholar
• Sultan E, Cantalloube C, Patat A, et al. Telithromycin (HMR 3647), the first ketolide antimicrobial, does not require dosage adjustment in individuals with hepatic impairment. Clin. Microbial Infect. 6\(Suppl. 1), 203 (2000) (Abstract MoP249).
   Google Scholar
• Aventis Pharma. Ketek (telithromycin), Drug Interactions. In: Briefing Document for the FDA Anti-Infective Drug Products Advisory Committee Meeting. Aventis Pharma, NJ, USA, 59–62 (2001).
   Google Scholar
• Scholtz HE, Pretorius SG, Wessels DH, et al. HMR 3547, a new ketolide antimicrobia, does not affect the pharmacodynamics or pharmacokinetics of warfarin in healthy adult males. Clin. Infect. Dis. 29(4), 976 (1999) (Abstract 81).
   Google Scholar
• Lippert C, Leese PT, Sultan E. Effect of gastric pH on the bioavailability of telithromycin (HMR 3647). 11th European Congress of Clinical Microbiology and Infectious Diseases. Clin. Microbial Infect. 7\(Suppl. 1), 267 (2001) (Abstract P1269).
   Google Scholar
• Scholtz HE, Sultan E, Wessels D, et al HMR 3647, a new ketolide antimicrobial, does not affect the reliability of low-dose, triphasic oral contraceptives. Program and Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, CA, USA, 26–29 September 1999 (Abstract 81).
   Google Scholar
• Joint Formulary Committee. British National Formulary 46th Edition. British Medical Association and Royal Pharmaceutical Society of Great Britain, London, UK (2003).
   Google Scholar
• Pankuch GA, Visalli MA, Jacobs MR, et al Susceptibilities of penicillin-and erythromycin-susceptible and-resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents. Antimicrob. Agents Chemother. 42, 624–630 (1998).
   PubMed Web of Science ®Google Scholar
• Dubois J, St-Pierre C. In vitro activity of telithromycin, macrolides and quinolones against respiratory tract pathogens. 40th Interscience Conference on Antimicrob. Agents Chemother. Toronto, Canada, 17–20 September 2000.
   Google Scholar
• Felmingham D. Microbiological profile of telithromycin, the first ketolide antimicrobial. Clin. Microbial Infect. 7\(Suppl. 3), 2–10 (2001).
   PubMedGoogle Scholar
• Mittermayer H, Jebelean C, Bocksrucker A, et al. Activity of telithromycin (HMR 3647) against erythromycin-susceptible and-resistant isolates of Streptococcus pneumoniae and Streptococcus pyogenes from Austria. Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada, 17–20 September 2000 (Abstract 2145).
   Google Scholar
• Felmingham D, Robbins MJ, Leakey A, et al. The comparative in vitro activity of HMR 3647, a ketolide antimicrobial, against clinical bacterial isolates. Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada, 28 September-1 October 1997 (Abstract F–116).
   Google Scholar
• Hoban D, Zhanel G, Karlowsky J. In vitro activity of the novel ketolide HMR 3647 and comparative oral antibiotics against Canadian respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Diagn. Microbial Infect. Dis. 35, 37–44 (1999).
   Google Scholar
• Schulin T, Wennersten C, Ferraro M, et al Susceptibilities of Legionella spp. to newer antimicrobials in vitro. Antimicrob. Agents Chemother. 42, 1520–1523 (1998).
   Google Scholar
• Bonnefoy A, Girard A, Agouridas C, et al Ketolides lack inducibility properties of MLS, resistance phenotype. J. Antimicrob. Chemother. 40, 85–90 (1997).
   PubMed Web of Science ®Google Scholar
• Hamilton-Miller J, Shah S. Comparative in vitro activity of ketolide HMR 3647 and four macrolides against Gram-positive cocci of known erythromycin susceptibility status. J. Andmicrob. Chemother 41,649–653 (1998).
   PubMedGoogle Scholar
• Cooper C. Telithromycin integrated summary ofsafiot Anti-Infective Drugs Advisory Committee, US Food and Drug Administration (2003).
   Google Scholar
• Pullman J, Champlin J, Vrooman PS Jr. Efficacy and tolerability of once-daily oral therapy with telithromycin compared with trovafloxacin for the treatment of community acquired pneumonia in adults. Int. J Clin. Prac. 57, 377–384 (2003).
   PubMed Web of Science ®Google Scholar
• DeAbate C, Heyder A, Leroy B, Sidarous E, Backstrom J. Oral telithromycin (MHR 800 mg o.d.) for 5 days is well-tolerated and as effective as cefuroxime axetil (500 mg b.i.d.) for 10 days in adults with acute exacerbations of chronic bronchitis (AECB). Program and Abstracts of the 40th Interscience Confirence on Antimicrobial Agents and Chemotherapy Toronto, Canada, 17–20 September 2000 (Abstract 2228).
   Google Scholar
• Aubier M, AMons P, Leak A, et al. Telithromycin is an effective as amoxicillin/clavulanate in acute exacerbations of chronic bronchitis. Resp. Med. 96, 862–871 (2002).
   PubMed Web of Science ®Google Scholar
• Aubier M, AMons P, Leak A, et al. Efficacy and tolerability of a 5-day course of a new ketolide antimicrobial, telithromycin (HMR 3547), for the treatment of acute exacerbations of chronic bronchitis (AECB) in patients with COPD. Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada, 17–20 September 2000 (Abstract 2.241).
   Google Scholar
• Roos K, Brunswig-Pitschner C, Kostrica R, et al Efficacy and tolerability of once-daily therapy with telithromycin for 5 or 10 days for the treatment of acute maxillary sinusitis. Chemotherapy 48, 100–108 (2002).
   PubMed Web of Science ®Google Scholar
• Quinn J, Ziter P, Leroy B, et al. Oral telithromycin (HMR 3647) 800 mg once daily for 5 days is well-tolerated and as effective as oral darithromycin 250 mg twice daily for 10 days in group A-hemolytic streptococcal (GABHS) pharyngitis/tonsillitis. Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada, 17–20 September 2000 (Abstract 2229).
   Google Scholar
• Nieman R, Sharma K, Edelberg H, Caffe S. Correspondence on telithromycin and myasthenia gravis. Clin. Infic. Dis. 37, 1579 (2003).
   PubMedGoogle Scholar